Chimeric antigen receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency INB-619, a next generation γδ TCE targeting CD19, ...

In8bio Inc. has unveiled INB-600, its next-generation γδ T-cell-based T-cell engager (TCE) platform designed to address one of the shortcomings of current existing γδ TCEs, specifically insufficient ...

(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency INB-619, a next generation γδ TCE targeting CD19 ...

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma. 2 Commerce Drive Suite 100 ...

T cell engagers: which ones have been approved? Big pharmas have been in the T cell engager space for a good while now. In fact, pharma giant Amgen’s drug was the first of its kind to be approved by ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...